SAN FRANCISCO, Oct. 26, 2025 /PRNewswire/ — At the 2025 Transcatheter Cardiovascular Therapeutics® (TCT) Conference, Dr. Jarrod Frizzell of The Christ Hospital (Cincinnati, OH) presented real-world studies¹,² demonstrating that the EggNest™ Complete Radiation Protection System from Egg Medical, Inc. (Roseville, MN) dramatically reduces radiation exposure for all members of the interventional team — including physicians, nurses, and technologists — compared to traditional shielding methods. During X-ray–guided cardiovascular procedures, scatter radiation poses a well-documented occupational hazard for Cath lab personnel, contributing to increased risks of cancer, cataracts, and cardiovascular disease. Conventional lead aprons, while offering some protection, have led to a high prevalence of orthopedic injuries among operators and staff.
EggNest Complete
In the studies presented, the average operator scatter radiation dose during coronary and PCI procedures using the EggNest Complete System was only 0.16 mRem per case. For context, the annual occupational exposure limit in the U.S. is 5,000 mRem—meaning an operator would need to perform over 31,000 cases before nearing that limit. With the typical interventionalist performing 300–500 cases annually, this technology enables a career’s worth of procedures with minimal exposure, often without the need for heavy lead aprons.
Teamwide protection was also demonstrated: nurses and technologists recorded average exposures of just 0.03 mRem per case, further confirming the EggNest System’s ability to safeguard the entire room.
“Having a radiation protection system that consistently protects my entire team as well as or better than the heavy lead we wore in the past means we’re taking care of patients and ourselves,” said Dr. Jarrod Frizzell.
Dr. Robert Riley, Chief Scientific Advisor for Egg Medical and interventional cardiologist at Overlake Medical Center (Seattle, WA), added:
“These real-world results reinforce what prior studies have shown — the EggNest Complete System is the only solution proven to significantly reduce radiation exposure for every member of the team. By enabling staff to perform procedures with ultralight or no lead aprons, we can also dramatically reduce orthopedic injuries associated with traditional protection.”
Dr. Frizzell and colleagues are continuing their evaluation of the EggNest System in structural heart and electrophysiology procedures, expanding the evidence base for its use across a broad range of X-ray–guided interventions.
References
Comparison of Standard Shielding versus Next-Generation Radiation Shielding System with Light Lead Apron. Raviteja Guddeti, MD, Korey Haddox, DO, Stephen Rudick, MD, Jarrod Frizzell, MD, Christian W. Schmidt, MS, PhD, Sitaramesh Emani, MD, Timothy D. Henry, MD, Dean J. Kereiakes, MD, Robert Riley, MD, MS, Puvi Seshiah, MD, James Kong, MD, John D. Corl, MD, Samantha Tribble, RN, Becca Harper, DNP, Ashley Bias, RN, Santiago Garcia, MD. Presented October 26, 2025 at TCT 2025.
Comparative Effectiveness of a Novel Scatter Radiation Shielding System Versus Standard Shielding. Jarrod Frizzell, MD, Sergey Gurevich, MD, Christian W. Schmidt, MS, PhD, Sitaramesh Emani, MD, Raviteja Guddeti, MD, Korey Haddox, DO, Robert Riley, MD, MS, Timothy D. Henry, MD, Dean J. Kereiakes, MD, James Kong,MD, Stephen Rudick, MD, Samantha Tribble, RN, Becca Harper, DNP, Ashley Bias, RN, Santiago Garcia, MD. Presented October 26, 2025 at TCT 2025.
For further information, please contact:
Egg Medical Media Contact Susan Storm Manager, Marketing, Egg Medical, Inc. E-mail: sstorm@eggmedical.com
About Egg Medical
Egg Medical is a global leader in radiation protection technologies. Headquartered in Minnesota, the company was founded with the goal to reduce the scatter radiation exposure of physicians, surgeons, nurses, technicians and others who use x-ray imaging to perform life-saving diagnostic and therapeutic procedures for patients. The EggNest Complete System provides comprehensive, table-mounted shielding that integrates seamlessly into existing workflow to protect the entire team without compromising procedural efficiency. More information about Egg Medical is available at https://eggmedical.com.
BEIJING, CHINA – Media OutReach Newswire – 26 October 2025 – The historic Jebum-gang Lha-khang Temple in Lhasa, southwest China’s Xizang Autonomous Region (Tibet), has been transformed from a centuries-old place of worship and a former granary into a vibrant modern art center. This unique project has revitalized a key cultural site for a new generation.
The temple has a history of approximately 200 years and has murals from the Qing Dynasty (1644-1911), according to Chinese architect Xia Yujun.
Nestled in a bustling business street and residential area at an altitude of 3,650 meters, the temple has been a center of energy for the ancient city of Lhasa and an important carrier of local Tibetan culture. Its circular construction, ancient Tibetan pillars and verandas, and centuries-old murals were among the highlights that hit him between the eyes.
First built in the late 19th century, the Jebum-gang Lha-khang Temple is the only mandalic building, featuring a symbolic Buddhist symmetrical structure. After decades of use as a granary, it has been transformed into a popular place among visitors in pursuit of modern art, thanks to five years of efforts by Xia and his team.
The building has been given a new lease on life. Xia’s team carefully repaired faded murals and fire-damaged carvings, ensuring the original architecture and layout were preserved.
The true innovation, however, lies in its new function. After the basics of the temple were restored, the space was reused as a modern art space, without altering the original structure or the spatial flow. This sensitive transformation has created a dynamic dialogue between the old and the new.
The goal was to bring it back to life, Xia says.
The rebirth of the Jebum-gang Lha-khang Temple as a modern art center required a sensitive yet thorough technological upgrade, seamlessly weaving new infrastructure into the historic fabric of the building.
Facing a near-total reconstruction of its core systems, the project began by fortifying the structure against the elements. A advanced, three-layer waterproofing system was applied to the roof, to ensure that the murals inside would not be affected for the next decade, Xia explained.
The most ingenious integration involved the floor. Old elm-wood flooring was installed using a joist structure, under which the necessary pipeline and electrical systems were embedded, paving the way for sound, lighting and electrical equipment essential to future exhibitions, thus preserving the temple’s ancient aesthetic.
The lighting system was completely re-engineered for its new role.
The incandescent lights were replaced with special lamps for museum-grade illumination, reducing the harmful rays that could damage the murals, while simultaneously crafting an ambient atmosphere that allows viewers to experience the tranquility of this sacred building.
Through these careful interventions, the temple now possesses the robust, unseen framework of a contemporary art space, all while enhancing and protecting its historical soul.
The transformation of the Jebum-gang Lha-khang Temple into a modern art center was guided by a profound understanding of its multi-sensory nature. Xia describes Tibetan ancient architecture as a multi-sensory “5D or 6D” experience, encompassing scent, sound, light, and history.
This philosophy directly shaped the restoration. The goal was not just to repair a building, but to preserve this immersive sensory atmosphere while equipping it for a new purpose. The temple’s rebirth is thus a sensitive fusion where modern functionality serves to amplify, rather than diminish, the timeless multi-sensory experience of the ancient structure.
This approach of repurposing historic buildings as art centers or museums aims to raise awareness among young generation about conservation and inspire them to engage with the preservation of architectural heritage in Xizang.
(The Chinese term “Xizang” refers to southwest China’s Tibet Autonomous Region.)
The issuer is solely responsible for the content of this announcement.
Film Festival Showcases Global Mobile Filmmaking Excellence, Launches “SmallRig Mobile Filmmaking Co-Creation Initiative” to Empower Filmmakers Worldwide
MELBOURNE, Australia, Oct. 26, 2025 /PRNewswire/ — The 14th International Smartphone Film Festival, co-presented by Mobile Innovation Network & Association (MINA) and SmallRig, a global specialist in imaging solutions, kicked off in Melbourne, Australia, on October 24, celebrating the explosive growth of mobile storytelling with 57 works—53 films and 4 VR projects—from 21 countries. As a cornerstone of global mobile cinema, the event features thematic screenings, panel discussions, and cross-industry exchanges, spotlighting innovation and future trends in smartphone filmmaking.
Mobile narrative creators, mobile filmmakers, directors and industry experts conduct round table discussions around mobile video
This year’s festival underscores the global reach of mobile creativity, with entries spanning diverse cultural narratives from both established and emerging filmmaker and screen producers. Opening day highlights included the “International Mobile Innovation Screening,” which premiered 14 films from 12 countries—including China, the U.S., Nigeria, and India. A lively panel discussion, “Trend and New Directions in Smartphone Filmmaking,” brought together filmmakers, directors, and industry experts to debate the evolving landscape of mobile cinema, from technical advancements to aesthetics and shifting audience expectations.
The festival’s success reflects the shared vision of its co-organizers. Founded in 2013, SmallRig has established itself as a global leader providing creators with comprehensive solutions, including camera/smartphone mounting and steadying rigs, lighting and control systems, imaging device batteries, and audio equipment. Today, its products reach users in over 160 countries and regions, supporting a spectrum of creative scenarios—from livestreaming and vlogging to documentaries and Hollywood blockbusters.
On site guests of the 14th International Mobile Film Festival sign in, take photos and punch in
MINA, a global advocate for mobile storytelling, has been instrumental in fostering this community. MINA founder and festival curator Max Schleser noted a staggering 97.56% surge in submissions from 2024 to 2025, calling it a testament to mobile filmmaking’s growing influence. “Smartphones are redefining cinema—this festival celebrates creators who embrace this new wave in filmmaking,” he emphasized.
SmallRig joined as co-presenter this year, bringing its expertise in mobile filming rigs and global creator support. As part of this collaboration, SmallRig launched the Mobile Filmmaking Co-Creation Initiative – a global platform inviting creators to contribute to tool development, promote standout mobile-shot films, and collaborate on original projects. The initiative aimed to expand access to equipment, exposure, and creative partnerships across more than 160 countries. “We’re turning creators’ visions into reality,” said Li Dan, SmallRig representative. “This program embodies our commitment to ‘Free Your Dream’—empowering storytellers to push boundaries.”
SmallRig and Mina jointly released the “SmallRig Mobile Filmmaking Co-Creation Initiative”
As the festival unfolds, additional screenings at Federation Square in Melbourne will continue to showcase diverse talent. On October 27 at 6pm, “New Voices” will spotlight debut filmmakers and experimental screen productions, while October 28 at 6pm features “MINA’s Creative Category & #EcoSmartphoneFilms,” highlighting works exploring environmental themes and innovative storytelling techniques. The closing event on October 29 at 6pm will present the “Innovation Category” alongside a screening of “Youth United Will Never Be Defeated” (Transform Project), focusing on social change narratives from around the world.
“Smartphone filmmaking’s accessibility enables more great stories to be told in a lighter, more personal way,” said Zhou Yang, Founder of SmallRig. “We’ve seen mobile shooting grow into an integral part of everyday creation. SmallRig continues to innovate lightweight, integrated mobile shooting solutions that empower creators, making filmmaking more personal and universal.” Zhou continued.
HONG KONG SAR – Media OutReach Newswire – 26 October 2025 – The metabolic “Three Highs” – hyperglycemia, hypertension, and hyperlipidemia – demonstrate a strong collective impact on cardiovascular diseases. An interim report from the HEARTWISE study, led by the School of Nursing, LKS Faculty of Medicine at The University of Hong Kong (HKUMed), reveals that patients presenting with this metabolic triad face up to 70% risk of recurrent major adverse cardiovascular events within ten years. The study further establishes that different risk factor combinations yield significantly varied recurrence patterns. These findings, powered by the locally developed AI-driven P-CARDIAC risk assessment model, highlight new opportunities for precision treatment planning to reduce recurrence rates and alleviate long-term pressures on Hong Kong’s healthcare system.
Professor Celine Chui Sze-ling, Assistant Professor, School of Nursing (middle), and Dr David Lui Tak-wai (right), Specialist in Endocrinology, Diabetes & Metabolism, Clinical Assistant Professor, Department of Medicine, School of Clinical Medicine, and both from the LKS Faculty of Medicine at The University of Hong Kong (HKUMed) and Biu, patient with cardiovascular disease (left), present interim HEARTWISE findings. They encourage expanded patient participation to broaden P-CARDIAC’s implementation, supporting long-term goals of enhancing cardiovascular disease management and reducing Hong Kong’s healthcare burden.
High Prevalence and Clinical Complexity of the Metabolic Triad
The “Three Highs” represent a substantial health burden in Hong Kong. According to 2020–2022 population health survey, 8.5%, 29.5%, and 51.9% of residents aged 15–84 are affected by hyperglycemia, hypertension, and hyperlipidemia respectively. These conditions collectively drive cardiovascular mortality, accounting for one in five deaths in Hong Kong. Stroke alone claimed over 3,000 lives in 2023, ranking as the city’s fourth leading cause of death.
Dr David Lui Tak-wai, Specialist in Endocrinology, Diabetes & Metabolism, Clinical Assistant Professor, Department of Medicine, School of Clinical Medicine, HKUMed, explained the underlying pathology: “The ‘Three Highs’ damage the vascular endothelium through distinct biological pathways, accelerating atherosclerosis, luminal narrowing, and plaque formation. This significantly increases the risk of cardiovascular events such as coronary heart disease, heart failure, and peripheral arterial disease” He further detailed specific stroke risks, “Hyperglycemia increases the risks of ischemic and hemorrhagic stroke by 2.3-fold and 1.6-fold respectively, while hyperlipidemia substantially elevates ischemic stroke risk as well.”
“Mitigating severe event risk requires moving beyond individual biomarker management to embrace holistic vascular protection,” Dr Lui emphasised. “Current assessment relies heavily on physician experience and internationally-derived tools. A precision model built on local data and AI can transform this paradigm, enabling superior risk evaluation, tailored treatment strategies, and more effective patient communication – particularly regarding underappreciated risks such as lipid control.
Biu (pseudonym), a patient living with hypertension and diabetes, was hospitalized earlier this year after experiencing sudden chest tightness. During his stay, medical professionals discovered that two of his coronary arteries were severely blocked, necessitating immediate coronary angioplasty surgery.
This cardiovascular event has significantly altered Biu’s lifestyle. He now relies on long-term medication and has completely transformed his daily habits. Despite these changes, he continues to grapple with anxiety and uncertainty, as his condition places him at a higher risk for further health complications.
Biu believes that a risk prediction tool could serve as a valuable reference point, helping him gain clarity in planning his health goals. Such a tool would not only provide him with reassurance but also offer peace of mind to his family, whom he treasures deeply. ”
P-CARDIAC: Personalised Risk Stratification for Precision Treatment
Professor Celine Chui Sze-ling, Assistant Professor, School of Nursing, HKUMed, explained that P-CARDIAC was developed using up to 13 million electronic medical records from the Hospital Authority. By analysing over 120 risk variables while incorporating individual patient characteristics, the model generates personalised risk scores specifically validated for Chinese populations. To establish clinical utility, the HKU School of Nursing launched the HEARTWISE study in 2024. In collaboration with cardiologists, endocrinologists, pharmacists, and nurses, the study enrolled patients with previous cardiovascular events from public hospitals.
1) Over 90% of cardiovascular patients presented with at least one “Three Highs” condition By August 2025, the study had recruited 1,248 patients, with 94% exhibiting at least one metabolic disorder. Among these, approximately one-fourth presented with all three conditions while 42% had two concurrent disorders.
2) Ten-Year Recurrence Risk Reaches 70%, with Significant Variation Across Risk Profiles P-CARDIAC analysis revealed a 70% overall ten-year recurrence risk among patients with “Three Highs” components. This risk escalated to 72% for patients with all three disorders. Notably, patients with only hypertension and hyperlipidemia demonstrated an equally elevated 73% risk, underscoring the need for individualised management strategies based on specific risk combinations.
3) Stroke Survivors Face Particularly High Recurrence Rates Analysis of the 10% of participants who were stroke survivors showed a 74% risk of subsequent cardiovascular events within ten years, indicating a critical need for intensified monitoring and secondary prevention.
Professor Chui emphasised the clinical implications, “These findings demonstrate AI’s transformative potential in clinical decision-making. We recommend healthcare professionals from both public and private healthcare systems integrate P-CARDIAC into their practice for predicting major cardiovascular event risks and developing personalised treatment plans. We anticipate P-CARDIAC will enable multidisciplinary teams to optimise prevention strategies, improve resource allocation, and ultimately reduce the healthcare system’s long-term burden.”
The HEARTWISE study continues recruitment across six public hospitals: Queen Mary Hospital, Queen Elizabeth Hospital, Kwong Wah Hospital, Princess Margaret Hospital, Tuen Mun Hospital, and Pok Oi Hospital. The research aims to further validate P-CARDIAC’s effectiveness in improving patient outcomes and expanding its precision treatment applications. Patients receiving cardiovascular care in cardiology, internal medicine, or endocrinology departments at these institutions may participate. Interested individuals can contact the HKU School of Nursing research team at 3917 6643 or pcardiac@hku.hk.
The issuer is solely responsible for the content of this announcement.
About P-CARDIAC and HEARTWISE Study
The P-CARDIAC initiative represents a significant advancement in cardiovascular risk assessment tailored specifically for the Hong Kong population. Developed through a collaborative effort between academic institutions and healthcare partners, P-CARDIAC utilises machine learning to provide personalised 10-year cardiovascular risk predictions for individuals with established acute coronary syndrome. The HEARTWISE study aims to validate the clinical utility of P-CARDIAC in real-world settings, ensuring that healthcare providers can effectively utilise this tool to enhance patient outcomes. By integrating pharmacist-led services into the management of cardiovascular conditions, HEARTWISE seeks to alleviate the burden on healthcare systems while improving the quality of care for patients.
The P-CARDIAC model represents a significant collaboration among key stakeholders aimed at improving cardiovascular risk assessment in Hong Kong. This initiative is led by principal investigator, Professor Celine Chui Sze-ling, Assistant Professor, School of Nursing, HKUMed, and co-principal investigator, Professor Ruibang Luo, Associate Professor of the Department of Computer Science, Faculty of Engineering, The University of Hong Kong.
The development of P-CARDIAC was supported by the Innovation and Technology Fund of the Innovation, Technology and Industry Bureau, with matching fund from Amgen Hong Kong, an international biopharmaceutical company focusing on developing pipeline medicines to address unmet medical needs while leveraging state-of-the-art science to drive solutions that improve health outcomes.
With the use of P-CARDIAC, the HEARTWISE study benefits from the active involvement of six hospitals under the Hong Kong Hospital Authority, which facilitates real-world implementation, data collection and comprehensive data analysis. Together, this study symbolises a multidisciplinary collaboration to commit advancing innovative and evidence-based strategies to address the rising burden of cardiovascular diseases.
Revenue from Continuing Operations[1]Reached RMB12.04 Billion, Up 19.7% YoY
Q1-Q3 Total Revenue: RMB32.86 Billion, Up 18.6% YoY;
Revenue from Continuing Operations Reached RMB32.45 Billion, Up 22.5% YoY
Q1-Q3 Net Profit Attributable to Owners of the Company Reached RMB12.08 Billion[2], Up 84.8% YoY;
Diluted Earnings per Share (EPS) of RMB4.21[3], Up 87.9% YoY
Q1-Q3 Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Reached RMB10.54 Billion, Up 43.4% YoY;
Adjusted Non-IFRS Diluted EPS of RMB3.68, Up 46.0% YoY
Backlog for Continuing Operations Reached RMB59.88 billion as of September 30, 2025, Up 41.2% YoY
Q1-Q3 Operating Cash Flow Achieved RMB10.87 Billion, Up 35.0% YoY
SHANGHAI, Oct. 26, 2025 /PRNewswire/ — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced financial results for the first three quarters ending September 30, 2025 (“Reporting Period”):
For the first three quarters of 2025, total revenue reached RMB32.86 billion, up 18.6% year-over-year. Revenue from Continuing Operations reached RMB32.45 billion, up 22.5% year-over-year.
Adjusted non-IFRS gross profit reached RMB15.46 billion, with the adjusted non-IFRS gross profit margin up 6.1pts year-over-year to 47.0%.
Net profit attributable to the owners of the Company was RMB12.08 billion, up 84.8% year-over-year; diluted EPS was RMB4.21, up 87.9% year-over-year.
Adjusted non-IFRS net profit attributable to the owners of the Company was RMB10.54 billion, up 43.4% year-over-year; adjusted non-IFRS net profit margin up 5.6pts year-over-year to 32.1%; adjusted non-IFRS diluted EPS was RMB3.68, up 46.0% year-over-year.
With continuous capacity expansion to better meet customer demand, backlog for Continuing Operations reached RMB59.88 billion as of September 30, 2025, up 41.2% year-over-year.
Operating cash flow climbed 35.0% year-over-year to RMB10.87 billion, driven by business growth, increase in operating efficiency, and continued improvement of financial management capabilities.
Sustained and steady business growth as a result of our unique, fully integrated Contract Research, Development and Manufacturing Organization (CRDMO) platform. Driven by “follow the molecule” and “win the molecule” strategies, WuXi Chemistry’s small molecule CRDMO pipeline continues to efficiently convert and capture high-quality molecules, delivering sustained business growth. In the first three quarters of 2025, a total of 621 new molecules were added to the small molecule Development and Manufacturing (D&M) pipeline. As of September 30, 2025, our small molecule D&M pipeline reached 3,430 molecules, representing an increase of 15 projects in phase III and commercial stages during the first three quarters of 2025.
Acceleration of global expansion,capacity construction and capability development. In March 2025, both the Changzhou and Taixing API manufacturing sites successfully passed FDA on-site inspections with no single observation. By the end of 2025, total reactor volume of small molecule APIs is expected to reach over 4,000kL. In September 2025, the construction of peptide capacity in Taixing was completed ahead of schedule; the Company’s total reactor volume of Solid Phase Peptide Synthesizers has been increased to more than 100,000L.
Robust shareholder returns. The Company remains committed to rewarding shareholders and actively supporting the Company’s value. This year, the Company has implemented a total of RMB6.88 billion in cash dividends, share repurchases and cancellations, representing more than 70% of the Company’s 2024 net profit attributable to the owners of the Company. Among these, the Company has distributed a total of RMB4.88 billion in cash dividends, including RMB2.83 billion for the 2024 annual cash dividend, RMB1.01 billion for the 2025 special cash dividend and RMB1.03 billion for the 2025 interim dividend. Meanwhile, the Company also completed the repurchase of RMB2.0 billion worth of A-shares in total, all of which have been cancelled.
[1] As disclosed in 2025 Third Quarterly Report, Continuing Operations include WuXi Chemistry, WuXi Testing, WuXi Biology and Others, the scope of which may change following adjustments to the Company’s business strategy.
[2] Net profit attributable to the owners of the Company is prepared in accordance with China Accounting Standards for Business Enterprises (CAS).
[3] In 2024 Q1-Q3 and 2025 Q1-Q3, WuXi AppTec had a fully-diluted weighted average share count of 2,906,724,914 and 2,873,641,499 ordinary shares, respectively.
2025 Full-Year Outlook
With confidence in customers’ ongoing demand for enabling services, our CRDMO business model and management execution, the Company has further raised its full-year guidance.
The Company expects Continuing Operations revenue to resume double-digit growth in 2025, with its year-over-year growth rate raised to 17-18%, up from the prior 13-17%. As a result, the Company expects full-year total revenue of RMB43.5-44.0 billion, up from the prior RMB42.5-43.5 billion.
As it focuses on the core CRDMO business and continuously improved production and operating efficiency, the Company is confident and expects to further improve the adjusted non-IFRS net profit margin in 2025.
The Company is actively advancing global capacity construction; while due to longer-than-expected settlement cycles of certain projects, capex for 2025 is expected to reach RMB5.5-6.0 billion (adjusted from the prior RMB7.0-8.0 billion). Together with business growth, efficiency improvement, and considering the timing differences in project payments, free cash flow for 2025 is expected to increase from RMB5.0-6.0 billion to RMB8.0-8.5 billion.
Management Comment
Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, “Reflecting robust customer demand and the strength of our unique CRDMO business model, WuXi AppTec delivered strong double-digit growth in revenue, profit and operating cash flow in the first three quarters of 2025, while our backlog for Continuing Operations reached a record RMB59.9 billion. Based on this momentum, we have further raised our full-year revenue and free cash flow guidance. The strategic divestment of clinical research services enables us to fully focus on our core CRDMO strategy and better meet the evolving needs of our customers. By concentrating on drug discovery, laboratory testing, process development, and manufacturing services, we are accelerating the growth of our global capabilities and capacities, delivering greater value for customers and shareholders, and advancing our vision that ‘every drug can be made and every disease can be treated’.”
Business Performance by Segment
WuXi Chemistry: CRDMO Business Model Drives Continuous Growth; Q1-Q3 2025 Revenue Up 29.3% YoY, with TIDES Revenue Up 121.1% YoY
Q1-Q3 revenue of WuXi Chemistry reached RMB25.98 billion, up 29.3% year-over-year. With continued optimization of production process and improvement in capacity efficiency driven by the growth of late-stage clinical and commercial projects, Q1-Q3 adjusted non-IFRS gross profit margin of WuXi Chemistry steadily improved 5.8pts year-over-year to 51.3%.
Small molecule drug discovery service (“R”) continues to generate downstream opportunities. In the past 12 months, we successfully synthesized and delivered more than 430,000 new compounds to customers. In the meantime, 250 molecules were converted from R to D phase in the first three quarters of 2025. Through our “follow-the-customer” and “follow-the-molecule” strategies, we established trusted partnerships with our customers globally, supporting the sustainable growth of our CRDMO business.
Small molecule D&M service remains strong.
The small molecule CDMO pipeline continued to expand. Q1-Q3 revenue of small molecule D&M services rose 14.1% year-over-year to RMB14.24 billion. In the first three quarters of 2025, 621 new molecules were added to the small molecule D&M pipeline. As of September 30, 2025, our small molecule D&M pipeline reached 3,430 molecules, including 80 commercial projects, 87 in phase III, 374 in phase II and 2,889 in phase I and pre-clinical stages. This represents an increase of 15 projects in the commercial and phase III stages during the first three quarters of 2025.
We continued to build small molecule capacity. In March 2025, both the Changzhou and Taixing API manufacturing sites successfully passed FDA on-site inspections with no single observation. The total reactor volume of small molecule APIs is expected to reach over 4,000kL by the end of 2025.
TIDES business (oligo and peptides) sustains rapid growth.
With the ramp-up of new capacities released sequentially each quarter last year, Q1-Q3 TIDES revenue grew 121.1% year-over-year to RMB7.84 billion. As of September 30, 2025, TIDES backlog grew 17.1% year-over-year.
TIDES D&M customers grew 12% year-over-year, while the number of TIDES molecules grew 34% year-over-year.
In September 2025, the construction of peptide capacity in Taixing was completed ahead of schedule; the Company’s total reactor volume of Solid Phase Peptide Synthesizers has been increased to more than 100,000L.
WuXi Testing: Drug Safety Evaluation Service & Site Management Organization (SMO) Maintain Leading Positions
WuXi Testing revenue reached RMB4.17 billion in Q1-Q3, and Q1-Q3 adjusted non-IFRS gross profit margin was 26.5%.
With development of differentiated capabilities and enhanced operational management, Q3 revenue of lab testing services reached RMB1.08 billion, growing 7.2% year-over-year and 7.5% quarter-over-quarter; while its Q3 adjusted non-IFRS gross profit margin continued to improve quarter-over-quarter. Of which, the revenue of drug safety evaluation services grew 5.9% year-over-year and 13.2% quarter-over-quarter.
Q1-Q3 revenue of lab testing services grew 2.7% year-over-year to RMB2.96 billion. Due to market impact, its Q1-Q3 adjusted non-IFRS gross profit margin declined as pricing was gradually reflected in revenue along with backlog conversion. Of which, drug safety evaluation services revenue resumed positive year-over-year growth, while maintaining an industry-leading position in the Asia-Pacific region.
The Company is committed to actively enabling customers’ global licensing. New modality business continued to develop, while the Company maintained its leading position in areas including nucleic acids, conjugates, mRNA, multispecific antibodies and peptides.
The Company continued to advance automation. DMPK successfully launched its proprietary all-in-one compound identification software, enhancing efficiency in spectral interpretation and metabolite identification for nucleic acids and peptides by 83%.
The Suzhou facility has successfully passed 4 consecutive FDA on-site inspections.
Q1-Q3 revenue for clinical CRO & SMO was down 6.4% year-over-year to RMB1.21 billion due to market pricing impact; of which, SMO revenue was down 0.7% year-over-year as backlog gradually converted into revenue, while maintaining its industry leading position in China.
During the first three quarters of 2025, our clinical CRO business supported customers in obtaining 19 IND approvals and submitting for 2 NDA filings; the SMO business supported 75 new drug approvals for customers. The SMO business has supported 331 new drug approvals in total over the past decade, maintaining significant advantages in multiple areas (endocrinology, dermatology, lung cancer and cardiovascular disease, etc.).
WuXi Biology: Continues to Generate Downstream Opportunities; In Vitro & In Vivo Business Synergies and New Modality Business Drive Growth
WuXi Biology follows the science, continuously strengthens drug discovery capabilities in emerging areas and actively grows overseas businesses. It efficiently generates downstream opportunities for CRDMO model by continuously contributing more than 20% of the Company’s new customers.
Through cross-regional collaboration, comprehensive platform integration and integrated project transformation, we efficiently enable our customers worldwide. WuXi Biology revenue reached RMB1.95 billion in Q1-Q3 2025, a year-over-year increase of 6.6%.
Due to market pricing impact, Q1-Q3 adjusted non-IFRS gross profit margin of WuXi Biology was down 1.0pts to 37.0%. With continuously improved operational efficiency, its Q3 adjusted non-IFRS gross profit margin improved 1.5pts quarter-over-quarter.
We accelerated advancements in in vitro integrated screening technologies and continued to improve in vivo pharmacology capabilities, resulting in rapid year-over-year and quarter-over-quarter revenue growth. With its competitive edge continuously strengthened, the non-oncology business has achieved strong revenue growth, becoming an important contributor to business growth.
New modality drug discovery services continue to perform well, contributing more than 30% of WuXi Biology’s total revenue.
This release provides a summary of the results and does not intend to provide a complete statement relating to the Company, its securities, or any relevant matters herein that a recipient may need in order to evaluate the Company. For additional information, please refer to the WuXi AppTec 2025 Third Quarterly Results Presentation and 2025 Third Quarterly Report disclosed on the Company’s official website, as well as the Company’s disclosure documents and information on the Shanghai Stock Exchange, the Stock Exchange of Hong Kong Limited website. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.
Net profit attributable to the owners of the Company is prepared in accordance with China Accounting Standards for Business Enterprises (CAS), in currency of RMB. Besides, all other financial information disclosed in this press release is prepared in accordance with the International Financial Reporting Standards Accounting Standards (“IFRSs”), in currency of RMB.
The 2025 Third Quarterly Report of the Company has not been audited.
Third Quarter 2025 Results by Segments
Unit: RMB million
Segment
Revenue
Change
Adjusted non- IFRS Gross Profit
Change
Adjusted non-IFRS Gross Profit Margin
WuXi Chemistry
9,676.68
22.7 %
5,329.83
40.6 %
55.1 %
WuXi Testing
1,480.83
2.1 %
428.69
-10.0 %
28.9 %
WuXi Biology
695.67
5.9 %
264.49
1.8 %
38.0 %
Others
191.78
163.8 %
161.60
658.4 %
84.3 %
Discontinued Operations (Note 1)
12.47
-96.9 %
12.47
N/A
100.0 %
Total
12,057.43
15.3 %
6,197.08
38.4 %
51.4 %
First Three Quarters 2025 Results by Segments
Unit: RMB million
Segment
Revenue
Change
Adjusted non- IFRS Gross Profit
Change
Adjusted non-IFRS Gross Profit Margin
WuXi Chemistry
25,978.06
29.3 %
13,314.69
45.7 %
51.3 %
WuXi Testing
4,169.47
0.0 %
1,104.58
-26.1 %
26.5 %
WuXi Biology
1,947.27
6.6 %
720.38
3.8 %
37.0 %
Others
355.26
-10.5 %
258.90
24.1 %
72.9 %
Discontinued Operations (Note 1)
406.65
-66.5 %
56.49
N/A
13.9 %
Total
32,856.72
18.6 %
15,455.04
36.3 %
47.0 %
Note 1: In accordance with the IFRSs, the Company has classified the operations for which equity sale agreements were signed or sales were completed during the first three quarters of 2025 or the comparison year as discontinued operations.
Note 2: Any sum of the data above that is inconsistent with the total is due to rounding.
Consolidated Statement of Profit or Loss[4]– Prepared under IFRSs
RMB Million
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Revenue
12,057.4
10,461.1
32,856.7
27,702.0
Cost of sales
(6,050.8)
(6,063.8)
(17,737.9)
(16,603.8)
Gross profit
6,006.6
4,397.3
15,118.9
11,098.2
Other income
280.4
247.6
920.0
758.6
Other gains and losses
188.0
(602.5)
2,637.0
(394.1)
Impairment losses under expected credit losses
(“ECL”) model, net of reversal
(169.0)
(72.5)
(459.6)
(154.6)
Impairment losses of non-financial assets
(80.0)
–
(153.5)
–
Impairment losses of assets classified as held for sale
–
–
(120.7)
–
Selling and marketing expenses
(175.0)
(189.1)
(569.4)
(546.6)
Administrative expenses
(721.8)
(687.4)
(1,969.5)
(1,964.9)
R&D expenses
(311.2)
(317.7)
(825.7)
(954.0)
Operating Profit
5,018.1
2,775.7
14,577.4
7,842.5
Share of results of associates
199.9
87.1
440.1
202.9
Share of results of joint ventures
0.6
0.2
0.6
(4.0)
Finance costs
(88.8)
(58.2)
(257.6)
(187.2)
Profit before tax
5,129.7
2,804.7
14,760.5
7,854.3
Income tax expense
(1,583.8)
(484.0)
(2,830.9)
(1,252.7)
Profit for the period
3,545.8
2,320.8
11,929.6
6,601.6
Profit for the period attributable to:
Owners of the Company
3,514.6
2,293.1
11,801.9
6,532.9
Non-controlling interests
31.2
27.7
127.6
68.7
3,545.8
2,320.8
11,929.6
6,601.6
[4] If the sum of the data below is inconsistent with the total, it is caused by rounding.
Consolidated Statement of Profit or Loss[5] (continued) – Prepared under IFRSs
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Weighted average number of ordinary shares for calculating EPS
(expressed in shares)
– Basic
2,839,378,755
2,883,580,115
2,839,864,290
2,899,626,297
– Diluted
2,877,629,997
2,889,573,492
2,873,641,499
2,906,724,914
Earnings per share (expressed in RMB per Share)
– Basic
1.24
0.80
4.16
2.25
– Diluted
1.22
0.79
4.12
2.24
[5] If the sum of the data below is inconsistent with the total, it is caused by rounding.
Consolidated Statement of Financial Position[6]– Prepared under IFRSs
RMB Million
September 30,
December 31,
2025
2024
Non-current Assets
Property, plant and equipment
25,662.5
25,267.8
Right-of-use assets
1,837.0
1,874.8
Goodwill
866.0
972.4
Other intangible assets
420.1
601.0
Interests in associates
1,939.2
2,322.2
Interests in joint ventures
3.9
3.4
Deferred tax assets
512.9
473.1
Financial assets at fair value through profit or loss (“FVTPL”)
8,350.8
8,943.4
Other non-current assets
115.7
114.7
Biological assets
1,085.7
1,063.0
Total Non-current Assets
40,793.8
41,635.7
Current Assets
Inventories
6,011.0
3,532.1
Contract costs
929.0
912.2
Biological assets
903.7
955.5
Amounts due from related parties
115.5
89.3
Trade and other receivables
10,731.6
9,643.7
Contract assets
819.0
988.8
Income tax recoverable
42.8
87.2
Financial assets at FVTPL
3,561.0
1,234.0
Derivative financial instruments
1.8
–
Other current assets
742.3
734.1
Pledged bank deposits
57.5
22.1
Term deposits with initial term of over three months
3,921.4
4,865.6
Bank balances and cash
25,459.9
13,434.3
53,296.6
36,498.8
Assets classified as held for sale
515.7
2,191.3
Total Current Assets
53,812.3
38,690.2
Total Assets
94,606.1
80,325.8
[6] If the sum of the data below is inconsistent with the total, it is caused by rounding.
Consolidated Statement of Financial Position (continued)[7]– Prepared under IFRSs
RMB Million
September 30,
December 31,
2025
2024
Current Liabilities
Trade and other payables
7,746.5
7,025.5
Amounts due to related parties
7.9
15.3
Derivative financial instruments
2.9
202.0
Contract liabilities
2,565.7
2,251.0
Bank borrowings
5,282.1
1,278.6
Lease liabilities
179.9
224.2
Income tax payables
2,249.9
870.8
Convertible bonds
1,294.5
3,493.1
19,329.3
15,360.6
Liabilities directly associated with assets classified as held for sale
109.0
865.5
Total Current Liabilities
19,438.3
16,226.1
Non-current Liabilities
Bank borrowings
1,799.1
2,959.5
Deferred tax liabilities
433.7
522.4
Deferred income
929.9
985.6
Lease liabilities
532.7
546.6
Total Non-current Liabilities
3,695.4
5,014.1
Total Liabilities
23,133.6
21,240.2
Net Assets
71,472.5
59,085.6
Capital and Reserves
Share capital
2,965.7
2,888.0
Reserves
67,982.4
55,744.7
Equity attributable to owners of the Company
70,948.1
58,632.7
Non-controlling interests
524.4
452.9
Total Equity
71,472.5
59,085.6
[7] If the sum of the data below is inconsistent with the total, it is caused by rounding.
Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company[8]
RMB Million
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024
Net profit attributable to the owners of the Company under CAS
3,514.6
2,293.1
12,075.5
6,532.9
GAAP difference[9]
–
–
(273.6)
–
Net profit attributable to the owners of the Company under IFRSs
3,514.6
2,293.1
11,801.9
6,532.9
Add:
Share-based compensation expenses
249.9
79.4
426.3
244.4
Issuance expenses of convertible bonds
8.7
–
28.4
–
Foreign exchange related losses
100.0
629.8
548.0
658.7
Amortization of acquired intangible assets from merger and acquisition
6.7
13.3
20.5
40.3
Gains or losses from divestiture, restructuring and resource integration initiatives
88.4
–
228.3
–
Non-IFRS net profit attributable to the owners of the Company
3,968.5
3,015.6
13,053.5
7,476.3
Add:
Realized and unrealized losses(gains) from venture capital investments
254.4
(41.9)
(2,515.7)
(134.6)
Realized and unrealized share of (gains)losses from joint ventures
(0.6)
(0.2)
(0.6)
4.0
Adjusted non-IFRS net profit attributable to the owners of the Company
4,222.3
2,973.5
10,537.1
7,345.7
[8] If the sum of the data below is inconsistent with the total, it is caused by rounding.
[9] Due to differences in accounting treatment of long-term equity investments under IFRSs, it occurs GAAP difference of RMB(273.6) million for first three quarters of 2025.
About WuXiAppTec
WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at https://www.wuxiapptec.com.
Forward-Looking Statements
This press release may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, our ability to meet timelines for the expansion of our service offerings or to reach the scale of our production capacity expansion plans, our ability to protect our clients’ intellectual property, competition, unforeseeable change of international policy, the impact of emergencies and other force majeure. Our forward-looking statements do not constitute any profit forecast by our management nor an undertaking by WuXi AppTec Co., Ltd. (“WuXi AppTec” or the “Company”) to our investors. ACCORDINGLY, YOU ARE STRONGLY CAUTIONED THAT RELIANCE ON ANY FORWARD-LOOKING STATEMENTS INVOLVES KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement or information in this press release to reflect future events or circumstances, except as required under applicable law.
Continuing Operations and Discontinued Operations
In accordance with the IFRSs, the Company has classified the operations for which equity sale agreements were signed or sales were completed during the first three quarters of 2025 or the comparison year as discontinued operations (“Discontinued Operations”). The remaining operations of the Company will continue to be reported as continuing operations (“Continuing Operations”).
Use of Non-IFRS and Adjusted Non-IFRS Financial Measures
We provide non-IFRS gross profit and non-IFRS net profit attributable to the owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, foreign exchange-related gains or losses, amortization of acquired intangible assets from merger and acquisition, gains or losses from divestiture, restructuring and resource integration initiatives, etc. We also provide adjusted non-IFRS net profit attributable to the owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither of the above is required by, or presented in accordance with IFRSs.
We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such non-IFRS financial measures, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRSs. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRSs, or as being comparable to results reported or forecasted by other companies.
HONG KONG, Oct. 26, 2025 /PRNewswire/ — As the global shift towards electric mobility reaches a pivotal crossroads, breakthroughs in technology, infrastructure and sustainability are converging to create a landscape rich in both opportunities and challenges. To bring together global expertise and accelerate the transition, the 2025 International Forum on New Journey of Electric Vehicle Revolution was successfully held in Hong Kong today, hosted by The Greater Bay Area Association of Academicians (GBAAA) and co-organised by the International Academicians Science and Technology Innovation Centre and the Research Centre for Electric Vehicles at The Hong Kong Polytechnic University.
The forum, themed “Strengthening Electrification & Advancing Intelligence,” brought together leading scholars, industry pioneers and policy experts from around the world. Discussions centred on three topics — Recent Advances in Electric Mobility, Powertrains, Batteries and Hydrogen, and Electric Vehicles’ Interaction with Power Grids and Clouds. The forum aims to advance from intelligent connected vehicles to intelligent transportation, smart cities, and ultimately an intelligent society — realising the vision that “Mobility is Freedom, Mobility is Happiness. “
At the opening of the forum, Professor Nancy IP, Academician of the Chinese Academy of Sciences, Chair of GBAAA, and President of The Hong Kong University of Science and Technology, delivered the welcome remarks. She noted that Hong Kong exerts unique advantages in promoting electric vehicle technology and industrial collaboration across the Greater Bay Area, and even globally. Professor IP added that GBAAA is proud to provide this opportunity to strengthen electrification, advance intelligence, and build the integrated systems that will truly power the next chapter of the electric vehicle revolution.
In his opening remarks, Dr GE Ming, Acting Permanent Secretary for Innovation, Technology and Industry of the Government of the Hong Kong Special Administrative Region, emphasised that although Hong Kong is not a traditional automotive hub, it has long contributed to advancing electric vehicles through research and innovation. The research teams continue to explore breakthroughs in battery technology, new energy, materials science, and intelligent systems—bringing Hong Kong’s ingenuity to the forefront of EV innovation.
Dr GE further noted that the electric vehicle revolution is a global endeavour — a complex, collaborative undertaking that calls for innovation across technology, policy, infrastructure, markets, and talent. As both an international innovation and technology centre and a leading international financial centre, Hong Kong is well positioned to serve as a bridge that foster collaboration among government, industry, academia, research, investment and applications. Hong Kong aims to help accelerate the new journey of the electric vehicle revolution and contribute to building a greener, smarter, and more sustainable future of mobility.
In his keynote address, Professor CHEN Xuedong, Academician of the Chinese Academy of Engineering and Vice President of China Association for Science and Technology (CAST), remarked that new energy vehicles have become a shared global solution to climate change and sustainable development. He noted that China’s electric vehicle industry has made remarkable strides — expanding its market scale, advancing technological capabilities, and optimising its industrial ecosystem — all of which are injecting fresh momentum into global growth. Looking ahead, Professor CHEN said that CAST will continue to drive progress by formulating clear technological goals and roadmaps, fostering innovation zones for talent, and strengthening platforms for international collaboration. Through interdisciplinary and cross-sector cooperation, these initiatives aim to accelerate industrial innovation. He also expressed his hope that Hong Kong will leverage its institutional and geographical advantages to promote high-quality development of the electric vehicle industry.
At present, the global electric vehicle industry is undergoing a pivotal shift — from policy-driven growth to a dual engine powered by market forces and technological innovation. How to overcome the initial barriers of cost, range, and infrastructure, and move towards a deeper integration with energy, transportation, and urban systems, has become a shared challenge across the industry. Professor C.C. CHAN, Academician of the Chinese Academy of Engineering, Fellow of the Royal Academy of Engineering, Co-Founder of GBAAA, Distinguished Chair Professor at The Hong Kong Polytechnic University, and widely known as the Father of Asian Electric Vehicles, delivered a keynote speech titled “New Journey of Electric Vehicle Revolution.” He outlined a scientific development paradigm of “Electrification + Intelligence + Connectivity,” calling for scientists, engineers, entrepreneurs, and policymakers to collaborate closely and, through continued iteration, jointly seize the opportunities of industrial transformation. He further called for cross-sector partnerships and sustained innovation to drive smart mobility from technological breakthroughs to large-scale, citywide implementation. Professor CHAN also emphasised the need to strengthen international cooperation and secure a strategic position in the next phase of automotive evolution, fostering the healthy and sustainable growth of the global EV ecosystem.
The Forum featured a rich and wide-ranging agenda, bringing together distinguished speakers from academia, industry, and research institutions for keynote speeches and in-depth panel discussions. The impressive line-up of speakers included Mr Sean GREEN, President and CEO of BMW Group Region China; Mr YIN Tongyue, Chair of Chery Automobile; and senior executives from Chongqing Changan Automobile, Dongfeng Motor, and Geely Research Institute, representing the forefront of the automotive industry. From the academic community, Professor James L. KIRTLEY JR., Member of the U.S. National Academy of Engineering, and Professor of the Massachusetts Institute of Technology, and Dr Don TAN, Member of the U.S. National Academy of Engineering and Vice President of IEEE , shared their insights. Also joining were renowned international experts such as Dr Kenji MORITA, Senior Expert of Japan Automobile Research Institute (JARI) and Dr Myron GRAW, Executive Director of Intelligent Production Systems, INC Innovation Centre, who contributed global perspectives on the evolution of electric mobility.
In his closing remarks, Professor Jin-Guang TENG, Academician of the Chinese Academy of Sciences, Vice Chair of GBAAA of Academicians, and President of The Hong Kong Polytechnic University, summarised the key takeaways of the day’s discussions. He noted that, in the face of climate change and global carbon reduction goals, electrification and smart mobility present significant opportunities for Hong Kong and the Greater Bay Area. While Hong Kong boasts world-class research capabilities and access to international capital, there remains a pressing need to strengthen the connection between research, technology transfer, and industrialisation. Leveraging the innovation and technology platforms in the Northern Metropolis, he suggested, could accelerate this process. Professor TENG also called for broader collaboration and greater alignment of standards across sectors to foster a globally connected ecosystem for green and intelligent mobility.
The successful convening of the 2025 International Forum on New Journey of Electric Vehicle Revolution marks a significant milestone in the global industry’s journey towards “Strengthening Electrification & Advancing Intelligence.” GBAAA will continue to leverage its strengths in scientific research and Hong Kong’s international connectivity to foster cross-disciplinary collaboration. At the same time, it will promote science education and public engagement in innovation, supporting collaborative innovation and technology development across the Greater Bay Area. Through these efforts, GBAAA aims to help Hong Kong and the wider region advance towards becoming a world-class innovation and technology centre, contributing to the nation’s scientific and technological progress.
Inaugural “Hong Kong Student Ambassador Programme for Chinese Medicine and Health Care” Graduation Ceremony Students Showcase Their Learning Outcomes
HONG KONG SAR – Media OutReach Newswire – 26 October 2025 – Beijing Tong Ren Tang Chinese Medicine Company Limited (“Beijing Tong Ren Tang”) (3613.HK) yesterday hosted the 10th anniversary retrospective exhibition of its “Tong Ren Tang Stroke Prevention Campaign” community health activity at its Tai Po Production and R&D Base. Over the past decade, Beijing Tong Ren Tang has consistently promoted stroke prevention awareness in communities, uniting diverse sectors through innovative activities to spread traditional Chinese medicine (TCM) culture and knowledge. Marking this 10th anniversary milestone, Beijing Tong Ren Tang has further stepped into schools this year, integrating culture with technology to pass on TCM and foster a future health community grounded in traditional wisdom. Through theoretical classes and interactive practices, it gradually builds sustainable community health mobilization while promoting the TCM concept of “Preemptive Health Practices.” This enhances Hong Kong citizens’ healthcare awareness and contributes TCM’s strengths to society’s overall health.
Students from the inaugural Beijing Tong Ren Tang “Hong Kong Student Ambassador Programme for Chinese Medicine and Health Care” attended the graduation ceremony and were awarded certificates of appreciation, officially becoming “Hong Kong Student Ambassadors for Chinese Medicine and Health Care.” They pledged to continue actively promoting traditional Chinese medicine health culture in the future.
New Programme Cultivates the Next Generation of TCM Ambassadors As a key project of this year’s “Tong Ren Tang Stroke Prevention Campaign,” Beijing Tong Ren Tang launched the inaugural “Hong Kong Student Ambassador Programme for Chinese Medicine and Health Care,” fully supported by China Mobile Hong Kong Company Limited (“China Mobile Hong Kong”) through its education brand “Edubile”, bringing the “Tong Ren Smart Green Chinese Herbal Medicine Cultivation Course” to Hong Kong campuses. Since its launch in March this year, the programme has attracted over 50 students from Caritas Ma On Shan Secondary School, Shun Tak Fraternal Association Yung Yau College, Yan Chai Hospital Law Chan Chor Si Primary School, S.K.H. Tin Shui Wai Ling Oi Primary School, and Yaumati Catholic Primary School. Through the course, students systematically learn traditional Chinese medicine knowledge, herbal planting techniques, and the development and application of modern Chinese medicine. In response to “World Stroke Day,” the participating students held a graduation ceremony yesterday at the Tai Po Production and R&D Base, sharing their learning outcomes and community service insights over the past few months.
Distinguished guests pose for a group photo at the celebration ceremony, including: Mr. Tsang Yok Sing, Independent Non-Executive Director, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. (middle), Mr. Yan Han, Executive Director and the Chairman of the Board, Beijing Tong Ren Tang Chinese Medicine Co., Ltd. (8th from left), Mr. Zeng Shendian, Vice President of Hong Kong Chinese Enterprises Association (7th from right) and Mr. Carl Su, Director of Cloud Products, China Mobile Hong Kong Company Limited (7th from left) celebrating the successful holding of the 10th “Tong Ren Tang Stroke Prevention Campaign” series of activities, practicing the concept of “Inheriting Traditional Chinese Medicine, Inspiring a Smarter Future.”
Over the past few months, students not only learned to plant herbs firsthand but also utilized the 5G+AIoT technology provided by Edubile to observe, record, and analyze plant growth data, effectively cultivating a scientific research spirit and innovative thinking. Throughout the programme, they visited Beijing Tong Ren Tang’s Tai Po Production and R&D Base, toured the Beijing Tong Ren Tang Cultural Museum and production lines, and visited China Mobile Hong Kong’s 5G Lab for hands-on experiences, engaging with traditional Chinese medicine experts and technology specialists. The programme has effectively and comprehensively deepened students’ understanding of the integration of the traditional Chinese medicine industry with technology. In off-campus visits and practical activities, students personally experienced the intangible cultural heritage pill-rolling technique, from material preparation to forming honey pills—each step required precise control of force and technique—allowing students to appreciate the craftsmanship and unique charm of traditional skills. Additionally, students learned about the practical benefits of traditional Chinese herbal sachets and specially made them to bring into the community. There, they joined stroke prevention health lectures, gifted the sachets to the elderly, and disseminated stroke prevention knowledge, truly putting into practice the programme’s concept of “Inheriting Traditional Chinese Medicine, Inspiring a Smarter Future.”
The Inaugural Beijing Tong Ren Tang “Hong Kong Student Ambassador Programme for Chinese Medicine and Health Care” concluded successfully.
Mr. Tsang Yok-sing, Independent Non-Executive Director of Beijing Tong Ren Tang Chinese Medicine Company Limited, said: “In traditional concepts, milestone years—every five and ten—are big occasions. ‘Tong Ren Tang Stroke Prevention Campaign’ community health initiative has reached its tenth year. I sincerely congratulate them on their unwavering commitment over the decade, finding new directions through exploration and truly taking root in Hong Kong communities. Today is also the graduation ceremony for the ‘Hong Kong Student Ambassador Programme for Chinese Medicine and Health Care,’ where students have opened their eyes to traditional Chinese medicine culture through learning, which is highly meaningful. By collaborating with Edubile, Beijing Tong Ren Tang is helping young people understand traditional Chinese medicine, herbs, and advanced technology—this is the action of a responsible enterprise. Inspire a spark of curiosity now, and tomorrow’s leaders will shine on their own.”
Mr. Yan Han, Executive Director and the Chairman of the Board of Beijing Tong Ren Tang Chinese Medicine Company Limited, said: “Beijing Tong Ren Tang is rooted in Hong Kong and concerned with citizens’ health, adhering to the original aspiration of ‘Nurturing Kindness and Virtue, Preserving Tranquility and Wellness,’ and earnestly fulfilling corporate social responsibility to give back to the broad support and trust of citizens. Over the past decade, we have continuously hosted the ‘Tong Ren Tang Stroke Prevention Campaign’ series of activities, extending from high-risk groups, vulnerable populations, and silver-haired communities to enterprises, workplaces, and youth in academia, connecting communities through diverse interactions and actively promoting the traditional Chinese medicine concept of ‘preventive treatment of disease,’ with cumulative investment exceeding 10,000 hours and generating over five million engagements. This year, we entered schools and jointly launched the inaugural ‘Hong Kong Student Ambassador Programme for Chinese Medicine and Health Care’ with China Mobile Hong Kong, combining traditional Chinese medicine cultural education with innovative technology practices, allowing students to deeply appreciate the craftsmanship of traditional Chinese medicine—this is a concrete action that embodies our concept of ‘Inheriting Traditional Chinese Medicine, Inspiring a Smarter Future.’ and we also hope this programme can set a successful example in the education sector. Looking ahead, we will focus on nurturing young students, actively promoting traditional medicine cultural education programmes, deeply cultivating the soil of traditional Chinese medicine culture, while helping enhance Hong Kong citizens’ healthcare awareness through integrated, everyday promotion models, contributing the strengths of traditional Chinese medicine to the overall health of Hong Kong society.”
At the graduation ceremony, students actively shared their learning experiences, including how to apply traditional Chinese medicine knowledge in daily life and how technological practices help cultivate environmental awareness and interdisciplinary thinking. A student from Yan Chai Hospital Law Chan Chor Si Primary School said that the off-campus visit to the Beijing Tong Ren Tang Cultural Museum and the hands-on pill‑rolling experience had opened their eyes. They had originally thought pill rolling looked easy, but when they tried it themselves, they realised it was difficult to master the force and technique and that they still needed to learn from the master. They added that they were truly grateful to the master for patiently teaching traditional skills and that the programme had taken them on a precious journey into traditional Chinese medicine culture.
Another student from Shun Tak Fraternal Association Yung Yau College said that the programme had not only taught them herbal cultivation and 5G technology applications but had also encouraged them to serve the community, broadening their horizons and enhancing their innovative thinking and sense of social responsibility. A student from S.K.H. Tin Shui Wai Ling Oi Primary School also said that planting herbs and visiting the 5G lab had helped them understand how technology supports the development of traditional Chinese medicine, and that they would continue to promote this knowledge to help more people prevent strokes.
Students who completed the course were awarded certificates of appreciation and officially became “Hong Kong Student Ambassadors for Chinese Medicine and Health Care,” committing to actively promote traditional Chinese medicine health culture in the future.
Entering Workplaces and Communities to Build Multi-Level Prevention Networks In addition to nurturing a new force in traditional Chinese medicine culture, this year’s “Tong Ren Tang Stroke Prevention Campaign” also moved into workplaces and continued to support elderly communities, providing tailored health support for people of different ages and lifestyles. For office workers, Beijing Tong Ren Tang collaborated with a number of enterprises to hold occupational health lectures, with Chinese medicine practitioners explaining stroke prevention knowledge, accompanied by Ba Duan Jin demonstrations and acupoint health guidance, along with on-site interactions and distribution of “Tong Ren Care Packages,” bringing practical workplace wellness and stroke prevention knowledge to offices. For the elderly, activities took place in community centers, combining health lectures, free clinics, herbal sachet workshops, and Ba Duan Jin exercises, with student ambassadors interacting with “Bronze Boy” to promote intergenerational harmony and comprehensively strengthen community stroke prevention mobilization.
A Decade of Caring: Linking Communities for Healthy Living
Yesterday, distinguished guests, teachers, and students also visited the “Tong Ren Tang Stroke Prevention Campaign” 10th anniversary retrospective exhibition, looking back together at the major milestones, wonderful moments, and community health achievements over the past decade. Over ten years, the initiative has cumulatively invested over 10,000 hours and generating over five million engagements. Even during the pandemic, the activities never stopped and distributed nearly 10,000 “Tong Ren Care Packages” to community elderly and those in need. In addition, Beijing Tong Ren Tang has continuously held stroke prevention health lectures and free clinics, conveying the traditional Chinese medicine concept of “Preemptive Health Practices” and key stroke prevention knowledge to citizens in lively and simple ways. Innovative activity formats include: creating the Guinness World Record for the “Largest Ba Duan Jin Learning Class,” launching the first stroke prevention traditional Chinese medicine mobile free clinic promotion vehicle, producing the “Care. Act in Time” microfilm and educational short films, organizing the “Walk with heart, Walk with love” and a children’s large-scale love mural co-creation activity, launching “Free Tram Day” to integrate health messages into everyday city life. At the same time, the “Tong Ren Tang Traditional Chinese Medicine Regimen and Culture Exhibition” was established at Ngong Ping Village, and the “Tong Ren Healthy” traditional Chinese medicine culture carnival and “Tong Ren A-Maze-ing Health Tips” mall activities were held, consistently and effectively spreading care, popularizing traditional Chinese medicine culture and wellness knowledge, and deepening public awareness of the importance of stroke prevention.
From now until 31 October 2025, customers shall enjoy a buy-2-get-1-free offer upon purchase of Beijing Tong Ren Tang Sporoderm-Broken Ganoderma Lucidum Spores Powder Capsules (90 capsules) or Tong Ren Tang Ganoderma Lucidum Vitality Capsules (90 capsules); enjoy 24% off upon purchase of Lingzhi Jianghuang Fufang Huoxue Anshen Capsules, Beijing Tong Ren Tang Sporoderm-Broken Ganoderma Lucidum Spores Powder Capsules (48 capsules), Ginseng-Antrodia Camphorata Capsule, Schisandra-Antrodia Camphorata Capsule, Cranberry Collagen Prebiotics, Reviving Prebiotics, Rhodiola Rosea Capsules, Blueberry Rhodiola Capsules, Marine Collagen Peptides, or Ultra-Fine Pearl Powder at designated Beijing Tong Ren Tang stores. The above discounts are based on standard price.
Special offer applicable at designated branches. Please scan the QR code for details on participating branches. Hashtag: #BeijingTongRenTang
The issuer is solely responsible for the content of this announcement.
About Beijing Tong Ren Tang
Tong Ren Tang was founded in 1669, and has a history of 356 years. The company has always adhered to its corporate motto of “No compromise on cost and labour despite the complexity of processing herbal medicine. No compromise on quality and standard despite the scarcity of medicine ingredients.” This commitment has led Beijing Tong Ren Tang to steady development, lasting through every generation, achieving excellence, and becoming a national treasure while expanding globally.
At the same time, Beijing Tong Ren Tang has taken on the mission of promoting traditional Chinese medicine culture, actively participating in domestic and international traditional Chinese medicine promotion activities, facilitating cultural exchanges around the world, and striving to expand the international influence of traditional Chinese medicine. To date, it has been operating over 160 retail branches in 26 countries and regions overseas, making it one of the most recognized traditional Chinese medicine brands internationally.
About Beijing Tong Ren Tang Chinese Medicine Company Limited
In 2004, Tong Ren Tang expanded its operations overseas by establishing Beijing Tong Ren Tong Chinese Medicine Company Limited in Hong Kong. Ahering to the corporate belief of “Nurturing kindness and virture, Preserving tranquility and wellness”, and with the mission of “Healthy Life, Globally Choice”, the company is based in Hong Kong while strategically positioning itself worldwide. It carries the mission of promoting traditional Chinese medicine culture outside mainland China. By employing a model that integrates medical services with medicine and emphasizes cultural outreach, the company is driving forward the internationalization of traditional Chinese medicine. (Beijing Tong Ren Tong Chinese Medicine Company Limited website: https://cm.tongrentang.com）
Blending mega events appeal with business opportunities and MICE visitors are invited to top-class wine-pairing experiences; in tandem, the HKTB launches new products to drive high-yield MICE tourism.
HONG KONG SAR – Media OutReach Newswire – 26 October 2025 – The annual flagship “Hong Kong Wine & Dine Festival” returns this year (23-26 October) with the vibrant theme “REMIX. BEST OF ALL WORLDS.” The Hong Kong Tourism Board (HKTB) took the opportunity to solidify Hong Kong’s reputation as a world-class epicurean capital and premier destination for business and leisure.
Hong Kong Top Travel Agent Awards Celebration & Gala Dinner 2025
The HKTB unveiled a series of strategic initiatives designed to engage high-yield visitors, and invited convention and exhibition visitors and travel agents from nine strategic markets to join in the festival. An exclusive sommelier wine-pairing private tour was arranged and an annual top agent award gala dinner was hosted to drive high-yield tourism and maximise the impact of mega events.
Along with the mega experience enhancement, the HKTB captured the opportunity to launch new incentive products in the “Hong Kong Incentive Playbook 2.0: New Discovery Product Update” on 24 October at Ocean Park Marriott Hotel, to drive high-yield MICE tourism.
MICE Meets Gastronomy: Top Agents Celebrate with Master Chefs’ Tasting Menu at Gala Dinner
The HKTB hosted over 80 top-tier travel agents from nine short-haul markets – Chinese Mainland, India, South Korea, Thailand, Indonesia, Malaysia, Singapore, Vietnam and The Philippines for a familiarisation trip from 22 October to 27 October, offering them a taste of the new incentive products in town, as well as recognising their achievements in bringing incentive groups to Hong Kong for the past year.
To celebrate their success, the HKTB hosted the prestigious “Toast to Success: Hong Kong Top Travel Agents Celebration & Gala Dinner”, where guests savoured an exquisite Cantonese dinner crafted by five master chefs, while being recognised for their roles in promoting Hong Kong. This underscored the city’s dual appeal as a global gastronomic hub and MICE powerhouse.
Guests enjoy an exquisite Cantonese dinner
Masterfully crafted dish by acclaimed chef
Performance by musicians at the Gala Dinner
Jennifer Ma, Executive President of Grand China MICE Holdings Co. Ltd., remarked that corporate groups from Chinese Mainland place particular importance on food, making the Hong Kong Wine & Dine Festival highly attractive to them. Participants can enjoy wine, and the format of the event allows them to deeply experience a sense of integration with local Hong Kong life. It also offers a cultural experience that blends East and West. “This kind of opportunity is especially popular among many young people in Chinese enterprises”, she noted. Additionally, she mentioned that the upgraded Hong Kong Incentive Playbook 2.0 together with its new ‘Empowerment’ theme and HKTB’s curated familiarisation trip in Hong Kong provided insights into many new tourism resources, such as events and venues, which will help Chinese Mainland enterprises better plan future MICE travel activities to Hong Kong.
Hong Kong Incentive Playbook 2.0: New Discovery Product Updates to Refresh Appeal
Hong Kong Incentive Playbook 2.0 trade briefing
Coinciding with the Festival, HKTB unveiled the upgraded “Hong Kong Incentive Playbook 2.0: New Discovery” on 24 October at a gathering of close to 300 agents and industry partners. Expanding on the first edition’s success, Playbook 2.0 delivers 200+ fresh experiences, from fencing workshops and billiard masterclasses to tours of grand auction houses, iconic movie sets and traditional Chinese temples, immersing MICE travellers in Hong Kong’s vibrant culture. Two new themes —Cruise and Empowerment— have been added to broaden itinerary possibilities, blending team-building thrills with personal enrichment and taking the excitement to the sea, ensuring both professional growth and unforgettable moments in Victoria Harbour. Some of the ideas were curated for a sneak peek during the mega familiarisation trip from 22-27 October.
Anthony Lau, Executive Director of the HKTB, delivers opening remarks
Distinguished guests enjoy the Hong Kong Incentive Playbook 2.0 trade briefing
Hong Kong Incentive Playbook 2.0
Ornnichcha Chomraka of Bonus Travel, Thailand said that the Hong Kong Wine & Dine Festival, held in late October, coincides with public holidays in Thailand, making it an ideal time for Thai food lovers to visit Hong Kong and enjoy the experience. She also observed a growing interest among companies in cruise tourism products. Many cruises operating out of Hong Kong include itineraries that visit other countries and regions, which helps her company expand and enrich its MICE travel offerings — for example, combining a two-day Hong Kong land itinerary with a cruise voyage. Convention and Exhibitions Visitors Staying Longer for Wine & Dine Thrills
To highlight the city’s seamless integration of business events and leisure experiences, the HKTB invited thousands of conventions and exhibition visitors from six business events to join the Festival 2025. The events spanned five key sectors – Legal Services, Aviation, Financial Services, Manufacturing and Trade. The allure of the vibrant Wine & Dine Festival encouraged overseas participants to prolong their stay, in order to explore and experience Hong Kong fully.
https://cm.tongrentang.com
https://www.facebook.com/beijingtongrentanghk
